Literature DB >> 18807033

Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT.

Matthias Miederer1, Stefan Seidl, Andreas Buck, Klemens Scheidhauer, Hans-Jürgen Wester, Markus Schwaiger, Aurel Perren.   

Abstract

PURPOSE: In clinical routine somatostatin analogue positron emission tomography/computed tomography (PET/CT) such as (68)Ga-DOTA-Tyr-octreotide (DOTATOC)-PET/CT could substitute conventional (111)In-Octreotide scintigraphy. Immunohistochemistry (IHC) for somatostatin receptor 2 (SSTR2) might be a tool to predict positivity of (68)Ga-DOTATOC in patients where initial staging was not performed, e.g., in incidental findings. We therefore compared a score of SSTR2-IHC with the in vivo standard uptake value (SUV) of preoperative or prebiopsy (68)Ga-DOTATOC PET/CT.
MATERIALS AND METHODS: In 18 patients, (68)Ga-DOTATOC PET/CT scans were quantified with SUV calculations and correlated to a cell membrane-based SSTR2-IHC score (ranging from 0 to 3).
RESULTS: Negative IHC scores were consistent with SUV values below 10. Furthermore, all score 2 and 3 specimens corresponded with high SUV values (above 15).
CONCLUSION: SSTR2-IHC scores correlated well with SUV values and we propose to use SSTR2 immunohistochemistry in patients missing a preoperative PET scan to indicate (68)Ga-DOTATOC-PET/CT as method for restaging and follow-up in individual patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18807033     DOI: 10.1007/s00259-008-0944-5

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  10 in total

Review 1.  Octreoscan radioreceptor imaging.

Authors:  Aart J van der Lely; Wouter W de Herder; Eric P Krenning; Dik J Kwekkeboom
Journal:  Endocrine       Date:  2003-04       Impact factor: 3.633

2.  Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary.

Authors:  Thomas Steinmüller; Reza Kianmanesh; Massimo Falconi; Aldo Scarpa; Babs Taal; Dik J Kwekkeboom; José M Lopes; Aurel Perren; George Nikou; James Yao; Gian Franco Delle Fave; Dermot O'Toole
Journal:  Neuroendocrinology       Date:  2007-11-21       Impact factor: 4.914

3.  Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use.

Authors:  J C Reubi; J C Schär; B Waser; S Wenger; A Heppeler; J S Schmitt; H R Mäcke
Journal:  Eur J Nucl Med       Date:  2000-03

4.  Molecular imaging as in vivo molecular pathology for gastroenteropancreatic neuroendocrine tumors: implications for follow-up after therapy.

Authors:  Eric P Krenning; Roelf Valkema; Dik J Kwekkeboom; Wouter W de Herder; Casper H J van Eijck; Marion de Jong; Stanislas Pauwels; Jean-Claude Reubi
Journal:  J Nucl Med       Date:  2005-01       Impact factor: 10.057

Review 5.  Radiolabeled somatostatin analog scintigraphy in oncology and immune diseases: an overview.

Authors:  D J Kwekkeboom; E P Krenning
Journal:  Eur Radiol       Date:  1997       Impact factor: 5.315

6.  Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy.

Authors:  Marco Volante; Maria Pia Brizzi; Antongiulio Faggiano; Stefano La Rosa; Ida Rapa; Anna Ferrero; Gelsomina Mansueto; Luisella Righi; Silvana Garancini; Carlo Capella; Gaetano De Rosa; Luigi Dogliotti; Annamaria Colao; Mauro Papotti
Journal:  Mod Pathol       Date:  2007-09-14       Impact factor: 7.842

7.  Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2 expression: new prognostic factors for malignant well-differentiated endocrine tumors.

Authors:  Amani Asnacios; Frédéric Courbon; Philippe Rochaix; Eric Bauvin; Valérie Cances-Lauwers; Christiane Susini; Stefan Schulz; Andrée Boneu; Rosine Guimbaud; Louis Buscail
Journal:  J Clin Oncol       Date:  2008-02-20       Impact factor: 44.544

8.  PET/CT with Gluc-Lys-([(18)F]FP)-TOCA: correlation between uptake, size and arterial perfusion in somatostatin receptor positive lesions.

Authors:  Hinrich Wieder; Ambros J Beer; Thorsten Poethko; Guenther Meisetschlaeger; Hans-Juergen Wester; Ernst Rummeny; Markus Schwaiger; Alexander R Stahl
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10-03       Impact factor: 9.236

9.  Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours.

Authors:  I Buchmann; M Henze; S Engelbrecht; M Eisenhut; A Runz; M Schäfer; T Schilling; S Haufe; T Herrmann; U Haberkorn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-05-23       Impact factor: 9.236

10.  Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?

Authors:  P Antunes; M Ginj; H Zhang; B Waser; R P Baum; J C Reubi; H Maecke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-01-16       Impact factor: 10.057

  10 in total
  55 in total

1.  [Quantification of immunohistochemical expression of somatostatin receptors in neuroendocrine tumors using 68Ga-DOTATATE PET/CT].

Authors:  A R Haug; G Assmann; C Rist; R Tiling; G P Schmidt; P Bartenstein; M Hacker
Journal:  Radiologe       Date:  2010-04       Impact factor: 0.635

2.  99mTc-HYNIC-TOC increased uptake can mimic malignancy in the pancreas uncinate process at somatostatin receptor SPECT/CT.

Authors:  Lilian Yuri Itaya Yamaga; Guilherme Campos Carvalho Neto; Marcelo Livorsi da Cunha; Akemi Osawa; Julio Cesar Silveira Oliveira; Ricardo Quartim Fonseca; Solange Amorim Nogueira; Jairo Wagner; Marcelo Gusmão Funari
Journal:  Radiol Med       Date:  2015-11-12       Impact factor: 3.469

3.  Somatostatin Receptors in Lung Cancer: From Function to Molecular Imaging and Therapeutics.

Authors:  J Clay Callison; Ronald C Walker; Pierre P Massion
Journal:  J Lung Cancer       Date:  2011

4.  Role of (68)Ga-DOTATOC PET-CT in the diagnosis and staging of pancreatic neuroendocrine tumours.

Authors:  Rakesh Kumar; Punit Sharma; Pramod Garg; Sellam Karunanithi; Niraj Naswa; Raju Sharma; Sanjay Thulkar; Sneh Lata; Arun Malhotra
Journal:  Eur Radiol       Date:  2011-07-13       Impact factor: 5.315

5.  Successful Localization Using 68Ga-DOTATOC PET/CT of a Phosphaturic Mesenchymal Tumor Causing Osteomalacia in a Patient with Concurrent Follicular Lymphoma.

Authors:  Sejin Ha; Sujin Park; Hyunji Kim; Heounjeong Go; Seung Hun Lee; Ji Yoon Choi; Jung Yong Hong; Jin-Sook Ryu
Journal:  Nucl Med Mol Imaging       Date:  2018-09-12

6.  Correlation between 99mTc-HYNIC-octreotide SPECT/CT somatostatin receptor scintigraphy and pathological grading of meningioma.

Authors:  Shengjun Wang; Weidong Yang; Jinglan Deng; Jianning Zhang; Fucheng Ma; Jing Wang
Journal:  J Neurooncol       Date:  2013-05-09       Impact factor: 4.130

7.  Gallium-68 DOTATOC PET/CT in vivo characterization of somatostatin receptor expression in the prostate.

Authors:  Mila V Todorović-Tirnanić; Milan M Gajić; Vladimir B Obradović; Richard P Baum
Journal:  Cancer Biother Radiopharm       Date:  2014-01-22       Impact factor: 3.099

8.  Molecular imaging with ⁶⁸Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours.

Authors:  Daniel Kaemmerer; Luisa Peter; Amelie Lupp; Stefan Schulz; Jörg Sänger; Vikas Prasad; Harshad Kulkarni; Sven-Petter Haugvik; Merten Hommann; Richard Paul Baum
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-05-31       Impact factor: 9.236

9.  Role of 68Ga-DOTATOC PET/CT in initial evaluation of patients with suspected bronchopulmonary carcinoid.

Authors:  Balasubramanian Venkitaraman; Sellam Karunanithi; Arvind Kumar; G C Khilnani; Rakesh Kumar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-01-17       Impact factor: 9.236

Review 10.  [PET-CT for neuroendocrine tumors and nuclear medicine therapy options].

Authors:  K Scheidhauer; M Miederer; F C Gaertner
Journal:  Radiologe       Date:  2009-03       Impact factor: 0.635

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.